A correspondence published in The Lancet has engaged with a proposal to retire the term polycystic ovary syndrome — widely known as PCOS — in favour of a new designation: polyendocrine metabolic ovarian syndrome, or PMOS.
Where the Proposal Originated
The renaming effort was put forward by Helena J Teede and colleagues following a global consensus process. The initiative sought to address longstanding concerns about how the condition is described and understood, both within clinical settings and more broadly.
The Case Against the Current Name
One of the central objections to the existing terminology centres on the word polycystic. The authors of the correspondence indicated support for removing what they described as a misleading suggestion that the condition involves pathological cysts on the ovaries. This characterisation has long been considered an imprecise representation of the underlying biology, potentially contributing to confusion among those diagnosed with the disorder.
What the New Name Aims to Convey
The proposed term — polyendocrine metabolic ovarian syndrome — is intended to draw attention to the condition's broader hormonal and metabolic dimensions. According to the correspondence in The Lancet, the revised name is designed to reflect the multisystem burden that the disorder places on those affected, moving beyond a description rooted solely in ovarian appearance.
PCOS is a hormonal condition that affects reproductive-age individuals and is associated with a range of features including irregular menstrual cycles, elevated androgen levels, and metabolic disruptions. The degree to which the current name captures this complexity has been a point of ongoing discussion in the medical literature.
A Welcomed but Scrutinised Shift
The correspondence authors expressed general support for the direction of the proposed change, particularly the move away from terminology that implies structural ovarian pathology. At the same time, the piece reflects the kind of careful deliberation that typically accompanies proposals to alter established medical nomenclature — changes that carry implications for clinical documentation, patient communication, and research categorisation.
Renaming a condition as widely recognised as PCOS is not a straightforward undertaking. The term appears across decades of published research, diagnostic guidelines, and patient advocacy materials. Any transition to PMOS would require broad adoption across medical institutions and regulatory bodies to take meaningful effect.
The correspondence in The Lancet represents one contribution to what is likely to be a continuing discussion about whether the proposed terminology better serves both scientific accuracy and the needs of those living with the condition.